NEW YORK (GenomeWeb) – Interpace Diagnostics said after the close of the market on Tuesday that it has entered into a securities purchase deal with certain institutional investors that is expected to raise $3.7 million in net proceeds.

The investors have agreed to purchase 375,000 shares of Interpace's common stock at $6.75 per share, and 255,000 prefunded warrants to purchase common stock at $6.74 per share. The offering is expected to close on or about Jan. 6.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.